RxDoctor Payments Data

Robert Johnston, MD

Family Medicine · la Porte, TXNPI 1649272907

Payments from drug & device makers

$14,672in general payments, 2019–2025

Across 705 payments — averaging $20.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Biohaven Pharmaceuticals, Inc.$1K
  • AbbVie$1K
  • Amarin Pharma, Inc.$1K
  • GSK$1K
  • Novo Nordisk$837
  • plus $7K from 54 others

What the payments were for

  • Consulting fees$1,71212%
  • Food & beverage$12,52585%
  • Education$1061%
  • Other$3292%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca84$2,177
Biohaven Pharmaceuticals, Inc.8$1,318
AbbVie(2 entities)77$1,150
Amarin Pharma, Inc.74$1,109
GSK53$1,109
Novo Nordisk48$837
Nestle Healthcare Nutrition Inc.25$514
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)27$378
Pfizer20$351
DJO, LLC2$329
Boehringer Ingelheim18$315
Bayer16$301
Takeda Pharmaceuticals U.S.A., Inc.15$288
Johnson & Johnson16$249
Neurocrine Biosciences, Inc.9$243
Novartis13$233
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC17$210
Aimmune Therapeutics, Inc.9$207
Lilly USA, LLC12$203
Esperion Therapeutics, Inc.10$178
Jazz Pharmaceuticals Inc.10$177
Otsuka America Pharmaceutical, Inc.8$164
Astellas Pharma US Inc7$155
Teva Pharmaceuticals USA, Inc.8$138
Merz North America, Inc.3$131
Vivus LLC6$106
Avanir Pharmaceuticals, Inc.6$105
Amgen(2 entities)6$96
Antares Pharma, Inc.4$82
Halozyme Inc4$79
Vanda Pharmaceuticals Inc.4$75
Lundbeck LLC3$68
Indivior Inc.3$66
Exact Sciences3$64
Orexo US, Inc.4$61
Eisai Inc.3$60
Nalu Medical, Inc.1$58
Endo Pharmaceuticals Inc.4$56
Dexcom, Inc.3$55
Kowa Pharmaceuticals America, Inc.3$52
Axsome Therapeutics, Inc.2$51
Abbott3$47
Azurity Pharmaceuticals, Inc.2$46
Xeris Pharmaceuticals, Inc.2$46
Hikma Pharmaceuticals USA3$45
Ironshore Pharmaceuticals Inc.2$43
Paratek Pharmaceuticals, Inc.2$43
Tolmar, Inc.2$40
Globus Medical1$40
Boston Scientific2$39
Alnylam Pharmaceuticals Inc.2$38
Zyla Life Sciences, Inc.2$36
Idorsia Pharmaceuticals US Inc1$33
Merck2$31
Sumitomo Pharma America, Inc.1$30
Verity Pharmaceuticals Inc.1$28
Sentynl Therapeutics, Inc.2$28
Sanofi-aventis U.S. LLC1$27
Biohaven Pharmaceutical Holding Company Ltd.1$25
Avvisto Therapeutics, LLC1$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,672 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$87,727
Medicare patients
168
Services billed
1,378

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide99$154,422
Austedo XrDeutetrabenazine22$122,465
EliquisApixaban71$74,938
JardianceEmpagliflozin23$34,296
XareltoRivaroxaban27$29,716
MounjaroTirzepatide16$28,689
Bydureon BciseExenatide Microspheres20$27,311
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$27,311
FarxigaDapagliflozin Propanediol23$27,303
Tresiba Flextouch U-100Insulin Degludec16$19,732
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl82$17,911
JanuviaSitagliptin Phosphate12$14,399
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$14,359
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr22$13,810
MyrbetriqMirabegron18$13,251

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$837$154,42299 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$138$122,46522 claims
PfizerEliquis$351$74,93871 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$2,177$47,80858 claims
GSKTrelegy Ellipta, Anoro Ellipta$1,109$41,12140 claims
Boehringer IngelheimJardiance$315$34,29623 claims
Johnson & JohnsonXarelto$249$29,71627 claims
Lilly USA, LLCMounjaro$203$28,68916 claims
Hikma Pharmaceuticals USABuprenorphine-Naloxone, Morphine Sulfate$45$21,474140 claims
MerckJanuvia$31$14,39912 claims
Astellas Pharma US IncMyrbetriq$155$13,25118 claims
AbbVieSynthroid, Armour Thyroid$1,150$6,03061 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in la Porte

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →